Anhui HygeianCells EE001 vs HiCM-188 (allogeneic iPSC-cardiomyocytes)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Heart Failure

Shared mechanism: Cardiac cell therapy · full Heart Failure pipeline

Anhui HygeianCells EE001

Developed by Anhui HygeianCells BioMedical

Phase 1 in Heart FailureBiologic/cell agent
Weak signal

NCT06884111 · Phase 1 · completed

Only 6 people received the drug, all in a single open, unblinded group with no placebo or comparison arm, so any change seen cannot be attributed to the drug with confidence. No results have been posted yet.

No aligned efficacy figure on record for this race.

HiCM-188 (allogeneic iPSC-cardiomyocytes)

Developed by HELP Therapeutics

Phase 3 in Heart FailureCell therapy (iPSC-derived)
Partial signal

NCT03763136 · Phase 1/2 · completed

The trial randomized 20 participants to hPSC-CM therapy or a sham comparator consisting of coronary artery bypass surgery alone, with outcome assessors masked to treatment assignment. Its primary endpoints were clinical safety outcomes, but results are not posted and the small sample limits the strength of the evidence.

Next expected readout: June 2027 · NCT07496372 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Heart Failure

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAnhui HygeianCells EE001HiCM-188 (allogeneic iPSC-cardiomyocytes)
CV death or HF hospitalisation—Not reported—Trial running · NCT07496372
HF hospitalisation—Not reported—Trial running · NCT07496372
CV death—Not reported—Trial running · NCT07496372
KCCQ clinical summary, change—Not reported—Trial running · NCT07496372

CV death or HF hospitalisation

Anhui HygeianCells EE001
—Not reported
HiCM-188 (allogeneic iPSC-cardiomyocytes)
—Trial running · NCT07496372

HF hospitalisation

Anhui HygeianCells EE001
—Not reported
HiCM-188 (allogeneic iPSC-cardiomyocytes)
—Trial running · NCT07496372

CV death

Anhui HygeianCells EE001
—Not reported
HiCM-188 (allogeneic iPSC-cardiomyocytes)
—Trial running · NCT07496372

KCCQ clinical summary, change

Anhui HygeianCells EE001
—Not reported
HiCM-188 (allogeneic iPSC-cardiomyocytes)
—Trial running · NCT07496372
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Anhui HygeianCells EE001: no structured comparison results are available for Heart Failure.

HiCM-188 (allogeneic iPSC-cardiomyocytes): no structured comparison results are available for Heart Failure.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Anhui HygeianCells EE001's landscape · HiCM-188 (allogeneic iPSC-cardiomyocytes)'s landscape